HAVCR2 and glioblastoma: For example, adding anti-TIM-3 mAbs to an anti-PD-1 mAb therapy regimen prolonged median survival from 33 to 100 days and increased OS from 27.8 to 57.9% in model mice with glioblastoma [142].